Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Repros' IND for Proellex approved; phase II trial being planned

Sep. 17, 2007

XOMA-052 enters clinic for type 2 diabetes

Sep. 17, 2007

Positive results for Vernalis' phase I V-24343 program for weight loss

Sep. 17, 2007

Dose-dependent occupancy of brain CB-1 receptors seen with taranabant

Sep. 17, 2007

Pivotal phase III prophylactic HAE trial of Cinryze meets primary endpoint

Sep. 14, 2007

BioSante and FDA reach agreement on LibiGel development requirements

Sep. 14, 2007

Phenomix begins phase IIb trial of PHX-1149 for type 2 diabetes

Sep. 14, 2007

Phosphagenics to initiate phase II trials of TMP/Insulin for diabetes

Sep. 14, 2007

FDA Advisory Committees reaffirm current dosing practices for ESAs

Sep. 14, 2007

FDA opens Corcept's IND for Corlux for Cushing's syndrome allowing initiation of phase III study

Sep. 14, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Roche secures CE mark for Alzheimer’s blood test
BioWorld
Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of...